KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cost of Revenue (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Cost of Revenue data on record, last reported at $407.5 million in Q2 2025.

  • For Q2 2025, Cost of Revenue rose 9.57% year-over-year to $407.5 million; the TTM value through Jun 2025 reached $1.6 billion, up 13.86%, while the annual FY2025 figure was $1.7 billion, 7.89% up from the prior year.
  • Cost of Revenue reached $407.5 million in Q2 2025 per VRTX's latest filing, down from $423.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $423.4 million in Q4 2024 and bottomed at $192.3 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $305.0 million, with a median of $289.4 million recorded in 2022.
  • The widest YoY moves for Cost of Revenue: up 29.9% in 2023, down 8.58% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $247.4 million in 2021, then rose by 14.51% to $283.3 million in 2022, then rose by 29.9% to $368.0 million in 2023, then grew by 15.05% to $423.4 million in 2024, then dropped by 3.76% to $407.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $407.5 million in Q2 2025, $423.4 million in Q4 2024, and $392.6 million in Q3 2024.